1. Medtech Insight
  2. >>Policy & Regulation

Hypertension Experts Push For New Trial Of Renal Denervation To Show Efficacy

 
• By Reed Miller

Since Medtronic’s sham-controlled SYMPLICITY HTN-3 trial of its Symplicity renal denervation device failed to meet its primary efficacy endpoint, manufacturers developing renal denervation systems have been working with researchers and FDA to map the next steps in researching and developing this hypertension therapy.

Companies developing renal denervation systems to treat hypertension are working together with FDA and hypertension experts to map out the future of the technology in the aftermath of the disappointing SYMPLICITY HTN-3 results.

SYMPLICITY HTN-3, the first major sham-controlled trial of renal denervation in patients with uncontrolled hypertension, showed that treatment with

More from Regulation

More from Policy & Regulation